IDO1 and breast cancer: Adding indoximod, an inhibitor of the Indoleamine 2,3-dioxygenase 1 (IDO1) pathway, to taxane did not increase PFS in patients with HER2-metastasised BC as compared to taxane alone, according to a Phase II clinical study comprising 164 patients [205].